A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Inclusion Criteria:

• Signed informed consent.

• Age ≥ 18 years.

• Life expectancy of > 3 months, in the opinion of the investigator.

• Ability to take oral medications and willing to record daily adherence to sotorasibthrough the use of a written diary.

• Participant is currently receiving treatment with sotorasib alone or in combinationtherapy in an Amgen-sponsored trial that has met its endpoints or otherwise will bestopping (also referred to as parent study) and are continuing to receive clinicalbenefit in the opinion of the investigator.

• For a participant on combination therapy in their parent study, treatment with otheranti-cancer therapies is allowed provided it matches the parent study.

• Eastern Cooperative Oncology Group Performance Status of ≤ 2.

Exclusion Criteria:

• Participant had permanently discontinued from sotorasib study treatment in theparent study before the parent study's completion.

• Ongoing, unresolved toxicity requiring interruption of sotorasib treatment at thetime of the termination of the parent study.

• Local access to commercially available investigational product(s) at no cost to theparticipant as permitted by local/country regulation.

• Anticipated toxicities of sotorasib study treatment outweigh the clinical benefit tothe participant in the opinion of the investigator.

• Participant unlikely to be able to complete all protocol-required procedures,restrictions and requirements, in the judgment of the individual and investigator.

• Significant uncontrolled concomitant disease that could affect compliance withprotocol procedures or interpretation of results or that pose a risk to participantsafety, in the opinion of the investigator.

• Female participants of childbearing potential unwilling to use protocol-specifiedmethod of contraception during treatment and for an additional:

• 7 days after the last dose of sotorasib.

• 2 months after the last dose of panitumumab.

• Female participants who are breastfeeding or who plan to breastfeed while on studythrough:

• 7 days after the last dose of sotorasib.

• 2 months after the last dose of panitumumab.

• Female participants planning to become pregnant while on study through:

• 7 days after the last dose of sotorasib.

• 2 months after the last dose of panitumumab.

• Female participants of childbearing potential with a positive pregnancy testassessed at screening or day 1 by a highly sensitive urine or serum pregnancy test.

• Male participants with a female partner of childbearing potential who are unwillingto practice sexual abstinence (refrain from heterosexual intercourse) or usecontraception during treatment and for an additional 7 days after the last dose ofsotorasib.

• Male participants with a pregnant partner who are unwilling to practice abstinenceor use a condom during treatment and for an additional 7 days after the last dose ofsotorasib.

• Male participants unwilling to abstain from donating sperm during treatment and foran additional 7 days after the last dose of sotorasib.